|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15531554155515561557155815591560156115621563...15771578» |
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neumega (oprelvekin) / Astellas
Trial completion: Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Trial completion: Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=36, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Trial completion: Doxorubicin Plus External-Beam Radiation Therapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=30, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Emcyt (estramustine) / Pfizer, Nippon Shinyaku
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | irinotecan / Generic mfg.
Trial completion: Irinotecan in Treating Children With Refractory Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=181, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=82, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma (clinicaltrials.gov) - Feb 19, 2014
P3, N=702, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- semaxanib (SU5416) / Pfizer
Trial completion: SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Pfizer
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion: Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion, Surgery: Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed No longer recruiting --> Completed
- | Amdray (valspodar) / Novartis
Trial completion, IO biomarker, Metastases: Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers (clinicaltrials.gov) - Feb 19, 2014
P1, N=14, Completed, Sponsor: Washington University School of Medicine
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion: Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=16, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=24, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Suspended --> Completed
- | paclitaxel / Generic mfg.
Trial completion: Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=33, Completed, Sponsor: Eastern Cooperative Oncology Group
Suspended --> Completed Active, not recruiting --> Completed
- | dactinomycin / Generic mfg., vincristine / Generic mfg.
Trial completion: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma (clinicaltrials.gov) - Feb 19, 2014
P3, N=483, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Hexalen (altretamine) / Ipsen, Eisai
Trial completion: Altretamine and Etoposide in Treating Patients With HIV-Related Cancer (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Roswell Park Cancer Institute
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Completed No longer recruiting --> Completed
- | Neutrexin (trimetrexate) / Pfizer
Trial completion: Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=25, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Toremifene in Treating Patients With Desmoid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=72, Completed, Sponsor: Lutheran General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | peripheral blood stem cell transplantation / National Cancer Institute
Trial completion, Metastases: A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas (clinicaltrials.gov) - Feb 19, 2014
P2, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: A Study of Patients With AIDS Syndrome (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=5000, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- Rytelo (imetelstat) / Geron
Enrollment open: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=90, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
No longer recruiting --> Completed Suspended --> Recruiting
- | plerixafor / Generic mfg.
Trial initiation date: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=46, Recruiting, Sponsor: Genzyme, a Sanofi Company
Suspended --> Recruiting Initiation date: Feb 2011 --> Feb 2014
- | plerixafor / Generic mfg.
Enrollment change: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=46, Recruiting, Sponsor: Genzyme, a Sanofi Company
Initiation date: Feb 2011 --> Feb 2014 N=67 --> 46
- | plerixafor / Generic mfg.
Enrollment open: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=46, Recruiting, Sponsor: Genzyme, a Sanofi Company
N=67 --> 46 Active, not recruiting --> Recruiting
- || sorafenib / Generic mfg.
New P3 trial: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis (clinicaltrials.gov) - Feb 17, 2014
P3, N=83, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Votrient (pazopanib) / Novartis, BeiGene
New P2 trial, Metastases: GEIS-32: Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma (clinicaltrials.gov) - Feb 17, 2014
P2, N=70, Not yet recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
New P2 trial, Metastases: TR1US: Trabectedin First Line Therapy In Unfit Sarcoma Study (clinicaltrials.gov) - Feb 17, 2014
P2, N=24, Recruiting, Sponsor: Italian Sarcoma Group
- sorafenib / Generic mfg.
Enrollment change: Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) (clinicaltrials.gov) - Feb 16, 2014
P2, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting N=24 --> 15
- linsitinib (ASP7487) / VasaraGen
Enrollment closed, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Feb 16, 2014
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=24 --> 15 Recruiting --> Active, not recruiting
- Biomarker, Trial withdrawal: Studying Biomarkers in Samples From Younger Patients With Kidney Cancer (clinicaltrials.gov) - Feb 13, 2014
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Withdrawn
- Biomarker, Enrollment change: Studying Biomarkers in Samples From Younger Patients With Kidney Cancer (clinicaltrials.gov) - Feb 13, 2014
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Active, not recruiting --> Withdrawn N=40 --> 0
- Recentin (cediranib) / AstraZeneca, Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma (clinicaltrials.gov) - Feb 13, 2014
P1, N=57, Completed, Sponsor: National Cancer Institute (NCI)
N=40 --> 0 Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Trial initiation date: A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis (clinicaltrials.gov) - Feb 12, 2014
P1/2, N=15, Recruiting, Sponsor: Maine Medical Center
Active, not recruiting --> Completed Initiation date: Dec 2010 --> Feb 2014
- temozolomide / Generic mfg.
Enrollment change: Dose-Intense Temozolomide in Recurrent Glioblastoma (clinicaltrials.gov) - Feb 12, 2014
P2, N=58, Completed, Sponsor: Patrick Y. Wen, MD
Initiation date: Dec 2010 --> Feb 2014 N=20 --> 58
- || New P3 trial, Metastases: ISG/AIEOP EW-1: Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma (clinicaltrials.gov) - Feb 12, 2014
P3, N=220, Recruiting, Sponsor: Italian Sarcoma Group
- M032 / The University of Alabama
New P1 trial: M032-HSV-1: Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (clinicaltrials.gov) - Feb 12, 2014
P1, N=36, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- sirolimus / Generic mfg.
Enrollment open: A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis (clinicaltrials.gov) - Feb 12, 2014
P1/2, N=15, Recruiting, Sponsor: Maine Medical Center
N=20 --> 58 Terminated --> Recruiting
- temozolomide / Generic mfg.
Trial completion: Dose-Intense Temozolomide in Recurrent Glioblastoma (clinicaltrials.gov) - Feb 12, 2014
P2, N=58, Completed, Sponsor: Patrick Y. Wen, MD
Terminated --> Recruiting Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
Trial initiation date: Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus (clinicaltrials.gov) - Feb 11, 2014
P2, N=51, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Initiation date: Jan 2002 --> Jan 2005
- ||| irinotecan / Generic mfg.
Enrollment change, Metastases: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma (clinicaltrials.gov) - Feb 11, 2014
P2, N=77, Completed, Sponsor: Children's Oncology Group
Initiation date: Jan 2002 --> Jan 2005 N=46 --> 77
- ||||| dactinomycin / Generic mfg., vincristine / Generic mfg.
Enrollment change: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma (clinicaltrials.gov) - Feb 11, 2014
P3, N=483, Completed, Sponsor: Children's Oncology Group
N=46 --> 77 N=254 --> 483
- ||| Enrollment closed, Surgery: AREN0321: Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors (clinicaltrials.gov) - Feb 11, 2014
P2, N=291, Active, not recruiting, Sponsor: Children's Oncology Group
N=254 --> 483 Recruiting --> Active, not recruiting
- |||| irinotecan / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma (clinicaltrials.gov) - Feb 11, 2014
P2, N=77, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (clinicaltrials.gov) - Feb 10, 2014
P1, N=18, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- melphalan / Generic mfg.
Enrollment change: isolated lung perfusion with melphalan followed by pulmonary metastasectomy in patients with resectable pulmonary metastases of colorectal carcinoma, soft tissue sarcoma and osteosarcoma (EUDRACT) - Feb 9, 2014
P2, N=100, Ongoing, Sponsor: St. Antonius Hospital
Not yet recruiting --> Recruiting N=30 --> 100
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 100 N=55 --> 43
- cyclophosphamide / Generic mfg.
New P1 trial, Metastases: NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (clinicaltrials.gov) - Feb 9, 2014
P1, N=12, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center